Zimmer Biomet Holdings, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Zimmer Biomet Holdings, Inc. stock analysis ZBH overview
Bullish +75

Zimmer Biomet Announces First Quarter 2026 Financial Results

📈 First quarter net sales reached $2.087 billion, marking a 9.3% increase reported versus the prior year period.

💰 Diluted earnings per share were $1.22, representing a 34.1% increase compared to the same period last year.

📉 Adjusted diluted earnings per share stood at $2.09, reflecting a 15.5% year-over-year growth.

💵 The company generated $359.4 million in operating cash flow and $245.9 million in free cash flow for the quarter.

🤝 Chairman and CEO Ivan Tornos stated the business is showing solid strategic, operational, and financial progress.

🚀 Management raised its full-year 2026 guidance for adjusted EPS and free cash flow expectations based on current momentum.

💸 The company completed $250 million in share repurchases during the first quarter of fiscal 2026.

👩‍⚕️ Dr. Jonathan M. Vigdorchik was appointed as Chief Science, Technology and Medical Affairs Officer to oversee global technology portfolios including AI and robotics.

🤖 Clinical enrollment opened for mBôs, an autonomous robotic total knee arthroplasty system acquired from Monogram Technologies in India.

🦴 The G7 Acetabular System completed its first case following FDA 510(k) clearance in February 2026 for hip replacement surgeries.

🎤 Zimmer Biomet launched ROSA Knee with OptimiZe and showcased innovations at the 2026 American Academy of Orthopaedic Surgeons meeting.

🏆 The company was named to FORTUNE's list of America's Most Innovative Companies and Ethisphere's list of World's Most Ethical Companies.

🦵 The Phantom Curved TTC Nail System was launched by Paragon 28 to support hindfoot fusion procedures.

📊 Revenue growth included contributions from geography segments such as North America, Europe, Asia Pacific, Latin America, and Emerging Markets.

🏷️ Product category performance covered Technology & Data, Bone Cement, Surgical tools, and implants including Sports Medicine and Trauma.

⚠️ The guidance update excludes the projected impact of the Paragon 28 acquisition for the one-year anniversary period.

📞 An investor conference call was held today at 8:30 a.m. ET via webcast on the company's Investor Relations website.

🔢 Revenue increases were driven by constant currency growth of 6.8% and organic constant currency growth of 2.9%.

Bullish Signals
  • Zimmer Biomet reported first quarter net sales of $2.087 billion, representing a strong 9.3% increase year-over-year.
  • Adjusted diluted earnings per share reached $2.09, marking a significant 15.5% growth over the prior year period.
  • The company generated substantial operating cash flow of $359.4 million and free cash flow of $245.9 million in the first quarter.
  • Management raised full-year 2026 adjusted EPS and free cash flow guidance, demonstrating confidence in sustained operational momentum.
  • Zimmer Biomet completed $250 million in share repurchases during the first quarter, reflecting strength in their capital allocation strategy.
  • The company was named to FORTUNE's 2026 list of America's Most Innovative Companies and Ethisphere's World's Most Ethical Companies for the second consecutive year.
  • The autonomous robotic total knee arthroplasty system mBôs completed enrollment in its multi-center clinical study in India, a key milestone for future commercialization.
  • The G7® Acetabular System achieved FDA 510(k) clearance in February 2026 and successfully completed its first case using the next-generation implant.
  • The full commercial launch of ROSA® Knee with OptimiZe was showcased at the 2026 AAOS annual meeting, highlighting successful product innovation.
  • Paragon 28 subsidiary launched the Phantom® Curved TTC Nail System to support hindfoot fusion procedures, expanding its orthopedic portfolio.
Risk Factors
  • The article contains no negative aspects or risks; it exclusively reports strong financial growth, rising earnings guidance, product launches, and positive strategic milestones.
  • Consequently, a JSON array of negative points cannot be generated as per the requirement to extract only pessimistic elements from the provided text.
Full Analysis
Zimmer Biomet Holdings Inc., trading on NYSE and SIX under ticker ZBH, announced its first quarter financial results for the period ended March 31, 2026, reporting significant growth across multiple key metrics. First quarter net sales reached $2.087 billion, representing a 9.3% increase on a reported basis compared to the prior year. When excluding currency fluctuations, sales grew by 6.8%, and organic sales grew by 2.9%. Net earnings for the quarter were $238.1 million, while adjusted net earnings stood at $409.4 million. Diluted earnings per share rose to $1.22, marking a 34.1% increase year-over-year, with adjusted diluted EPS reaching $2.09, a 15.5% gain. The company generated $359.4 million in operating cash flow and $245.9 million in free cash flow during the quarter. CEO Ivan Tornos highlighted the solid strategic, operational, and financial start to the year, citing healthy end markets, momentum from recently launched products, and disciplined execution. Based on this progress and the planned go-to-market transformation, Zimmer Biomet is raising its full-year adjusted EPS guidance and free cash flow expectations for 2026. The company also noted that it completed $250 million in share repurchases during the first quarter of fiscal 2026. Additionally, several key personnel and product milestones were achieved, including the appointment of Dr. Jonathan M. Vigdorchik as Chief Science, Technology and Medical Affairs Officer to lead technology portfolios involving AI and robotics, and the completion of the first case using the G7 Acetabular System for hip replacements. The article details various clinical and commercial advancements, such as the enrollment in a multi-center clinical study for mBôs, an autonomous robotic total knee system acquired from Monogram Technologies, and the full commercial launch of ROSA Knee with OptimiZe at the American Academy of Orthopaedic Surgeons meeting. The company also received recognition for naming itself to Fortune's 2026 list of America's Most Innovative Companies and Ethisphere's World's Most Ethical Companies for the second consecutive year, alongside the launch of the Phantom Curved TTC Nail System from its Paragon 28 subsidiary. Zimmer Biomet updated its full-year 2026 financial guidance, noting a projected revenue change impacted by foreign currency exchange factors, with specific adjustments made to exclude the effects of the April 2025 acquisition of Paragon 28 Inc. The company scheduled its investor conference call for April 28, 2026, at 8:30 a.m. ET.